Posted by Michael Wonder on 19 Feb 2019
New early breast cancer drug to be made available in Singapore via Special Access Program
17 February 2019 - Subsidised Singapore Special Access Program open today to patients with HER2-over-expressing cancers.
A new breast cancer drug shown to significantly reduce the risk of cancer recurrence is being made available to women in Singapore from today via a Special Access Program.
The drug, Nerlynx (neratinib) is an oral medication taken by women with HER2+ breast cancer who have completed adjuvant trastuzumab-based therapy.
